Ann: ATL1103 Update, page-7

You are spot on Sander.
Last announcement signed by Diamond :
"Antisense Therapeutics (“ANP” or the “Company”) has initiated the process for submission of the ATL1102 for Multiple Sclerosis (MS) Phase IIb IND application with documentation being provided to its Regulatory Agent in the US who, on the Company’s behalf, will submit the IND application to the US Food and Drug Administration (FDA). This submission process is expected to be completed in May"

I wonder how long the initiated process will go for as in today ann there is no mention of it and we are
already passed mid may.

But instead today Diamond announced:
"ATL1103 partnering interactions .ANP continues its discussions with potential development and commercialization partners on the ongoing development of ATL1103 and as part of this process has provided confidential information on ATL1103 under relevant non-disclosure agreements. The Company will advise the market should any of these interactions lead to a material partnering commitment. It is the Company’s view that providing any estimated guidance on the timing or other aspects of these discussions could disadvantage potential partnering outcomes."

Which does not mean anything. We do not know for sure if these discussions are really taking place the way is
worded does not confirm the existence of any really interested party and cannot be verified due to the inclusion
of foll sentence:" ......confidential information on ATL1103........non-disclosure agreements" (yes right) and of
course : "The company will advise the market should any of these interactions lead to etc etc...."

Also referring to the publication for the very exited ITSA it should be noted the foll:Scientific Publication

1. A manuscript entitled “Antisense Oligonucleotide Therapy in Acromegaly: A Randomized Phase II Study” has recently been submitted for publication in a high-quality peer reviewed scientific journal. "
   
   It says that a manuscript has recently been submitted for publication it does not say it will be published and
   does not even mention the name of the scientific journal.
   As previously stated all these ann do not mean anything at all it is a "smart" way for the Diamond
   to keep getting his salary for nothing concrete and it is reinforcing my opinion that under his leadership (?)
   the company will go nowhere. This time I am also starting to be sceptical about the real pipeline it self .
   I think we,as shareholders, should start to send several messages to Diamond with a please explain because
   I really feel we are taken for a never ending ride.